Sep. 3 at 12:12 PM
🚨
$MDCX : MAJOR PFIZER DEAL JUST DROPPED
Medicus Pharma just entered into a Co-Development & License Agreement with Pfizer for CD228V, an early-stage antibody-drug conjugate targeting CD228.
🔹 Exclusive worldwide license to develop and commercialize CD228V
🔹 Pfizer remains involved in the program and is providing
$2M in development funding
🔹 Pfizer has the option to fund all or part of development starting with the first pivotal trial
🔹 Medicus retains control over development, manufacturing, regulatory approval and commercialization
🔹 Agreement includes more than
$1 BILLION in potential development, regulatory and sales milestones
🔹 Pfizer is also eligible for low double-digit royalties on future net sales
This adds an entirely new oncology asset to the MDCX pipeline with Pfizer remaining directly involved in its development.
SECTOR PEERS:
$CRNX
$ARQT
$IMVT
$VTYX